BUY MBP BERACTANT SURVANTA 8ML INJ VIAL BEST PRICE ONLINE IN NIGERIA LAGOS ABUJA KANO AND PORTHARCOURT AT MYBIGPHARMACY.COM

Description

Dear friend, this medication requires a prescription or medical license before it can be delivered to you. kindly ensure that you provide us with a reliable contact information at checkout, mybigpharmacy team will be in touch with you to obtain required document before your order is confirmed thank you for trusting mybig pharmacy with your health. Beractant is a natural pulmonary surfactant used in newborn babies, especially premature infants, who have difficulty breathing due to a condition called respiratory distress syndrome. Respiratory distress syndrome occurs when a baby?s lungs do not produce enough natural surfactant, a substance that helps keep the air sacs in the lungs open. Without enough surfactant, the lungs collapse easily, making breathing extremely difficult and reducing oxygen levels in the body.

Beractant works by replacing or supplementing the baby?s natural surfactant. It lowers the surface tension inside the lungs, allowing the air sacs, called alveoli, to stay open during breathing. This improves oxygen exchange, reduces the effort needed to breathe, and helps stabilise the lungs. Beractant is derived from bovine (cow) lung extract and contains phospholipids and surfactant-associated proteins similar to those found in natural human surfactant.

Beractant is given directly into the lungs through a breathing tube that is already in place. It is administered by trained healthcare professionals in a neonatal intensive care unit. The medicine is delivered in divided doses while the baby is carefully positioned to allow even distribution throughout the lungs. After administration, the baby is closely monitored for breathing, oxygen levels, heart rate, and blood pressure.

Beractant is mainly used in premature infants who are at risk of respiratory distress syndrome or who already show signs of breathing difficulty shortly after birth. It may be given shortly after birth as a preventive treatment or later as a rescue treatment once symptoms appear. In some cases, more than one dose may be required, depending on the baby?s response and ongoing respiratory needs.

The benefits of beractant include improved lung function, better oxygenation, reduced need for high oxygen levels or mechanical ventilation, and a lower risk of complications related to severe respiratory distress. Early treatment with beractant has been shown to significantly improve survival and reduce lung injury in premature infants.

Like all medicines, beractant can have side effects, although many are related to the administration process rather than the medicine itself. Possible effects include temporary changes in heart rate, oxygen levels, or blood pressure during dosing. Some babies may experience brief airway obstruction, coughing, or reflux of the medicine. These effects are usually short-lived and managed by trained neonatal staff.

Serious side effects are uncommon but may include lung bleeding, infection, or uneven lung expansion. Because premature infants are medically fragile, continuous monitoring is essential during and after treatment. The benefits of beractant generally far outweigh the risks when used appropriately.

Beractant does not cause dependency and does not interfere with long-term lung development when used correctly. It supports the baby?s natural breathing until their own lungs mature enough to produce sufficient surfactant.

In summary, beractant is a life-saving medication used in newborns with respiratory distress syndrome. By replacing missing surfactant, it helps the lungs function properly, improves oxygen delivery, and supports survival and recovery during a critical period of early life.